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Interpretation of immunoblots for Lyme borreliosis 
using a semiquantitative approach 
Kurine RY$el1, Olivier Piter', Luc Binet' and Eric Duyer' 
'Infectious Diseases and Immunology, Institut Central des HGpitaux Valaisans, Son, "Labodla SA, 
Yens. Switzerland 
Objective: To test the performances of new Borrelia garinii immunoblots specific for Borrelia bwgdorferi sensu lato 
with a selected panel of sera from patients with various clinical presentations of Lyme borreliosis. 
Methods: In order to establish the sensitivity and the specificity of these immunoblots, we tested serum samples 
obtained from patients with early- and late-stage Lyme disease (erythema migrans n=35, nei.woborreliosis n=61, 
acrodermatitis chronica atrophicans (ACA) n=27 and arthritis n=41), from patients with diagnoses and laboratory 
findings associated with serologic cross-reactivity to Lyme disease (syphilis n=12, Epstein-Barr infection n=9, 
autoimmune markers n=29) and from blood donors residing in regions of low and medium endemicity (n=80, n=100). 
Results: The combined sensitivity (IgG and IgM) of the tests was 90% for patients with erythema migrans, 92% for 
neuroborreliosis. 96% for ACA and 100% for Lyme arthritis. The specificity of the IgG immunoblot was %YO, and that of 
the IgM immunoblot was 97%. taking into account the prevalence of borrelia antibodies in the overall population. 
Interpretation of these immunoblots is based on scores allocated to different specific borrelia antigens. 
Conclusions: The Western blot technology is extremely useful in dissecting the immune response to borrelia 
infections, which develops gradually over a period of weeks to years and which involves the appearance of IgM and IgG 
antibodies directed against a number of borrelia-associated proteins. 
Key words: Acrodermatitis, arthritis, Borrelia garinii, erythema migrans, immunoblots, Lyme borreliosis, neuro- 
borreliosis, sensitivity, specificity 
INTRODUCTION 
Lyme borreliosis is a tick-borne multistage disease 
which is caused by spirochetal bacteria, Borrelia 
buvgdo$ri sensu lato (B.  buvgdo$~i sensu stricto, B. gurinii, 
B. ajzelii, etc) [1,2]. It appears that the geographic 
distribution of these species is not uniform. In western 
Europe and in Switzerland, B. gurinii is most frequently 
isolated, followed by B. burgdoferi sensu stricto and B. 
ujzelii [3,4]. In Scandinavia and in The Netherlands, 
B. ufzelii is probably the most common Borrelia species 
Corresponding author and reprint requests: 
K. Ryffel, Infectious Diseases and Immunology, 
lnstitut Central des Hopitaux Valaisans, 
CH-1950 Son, Switzerland 
Tel: +41 27 324 53 91 
E-mail: karine.ryffeI@ichv.vsnet.ch 
Accepted 11 December 1997 
Fax: +41 21 203 29 15 
[S ] ,  followed by B. garinii and B. buydo$eri sensu stricto. 
Following the bite of an infected ti.ck, the spirochetes 
undergo a hematogenous dissemination and can be 
found in many of the major organ systems. The first 
stage and hallmark of Lyme borre11.osis is a distinctive 
skin rash, erythema migrans (EM), that frequently 
appears at the site of the tick bite. .Unfortunately, EM 
is present in or recalled by only 50-'70% ofpatients and 
the other signs of an early infection are variable and 
non-specific [6]. Days to months after the tick bite, the 
disease may progress towards secondary and tertiary 
stages. In Europe, neurologic symptoms appear in 30% 
of untreated patients and musculoskeletal symptoms 
in 20% of patients [7]. Late Lyme bmreliosis is charac- 
terized by arthritis, acrodermatitis chronica atrophicans 
(ACA) or neurologic symptoms, depending upon the 
Borrelia species involved. It appears that B. burgdo6eri 
sensu stricto is more frequently associated with arthritic 
con&tions [8 ] ,  B. garinii with neuro:logic symptoms [9] 
and B. afiefii with ACA [5,10]. However, controversial 
reports have been published concerning the absence of 
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associations between Borrelia species and clinical symp- 
toms [11,12]. 
Due to its wide and non-specific symptomatology, 
Lyme borreliosis has often been misdiagnosed and 
confused with multiple sclerosis, rheumatoid arthritis 
or viral meningitis, among other diseases. Thus diag- 
nosis of Lyme borreliosis relies on laboratory findings. 
Culture of B. burgdoferi sensu lato from clinical speci- 
mens, detection of genetic material by PCR or direct 
examination of tissue for spirochetes are difficult 
and impractical for routine testing 113,141. Today, the 
laboratory work-up of Lyme borreliosis relies on 
serologic tests. The standard approach involves screen- 
ing the patient’s sample using a technology such as 
ELISA or indirect immunofluorescent assay. Unfortu- 
nately various autoimmune diseases or viral syndromes 
may induce false-positive results. Cross-reactions of 
some borrelia proteins with antigens &om other bacteria 
are well known [15]. For these reasons, a confirmatory 
test such as immunoblotting is mandatory to report 
positive results. The US Center for Disease Control 
and Prevention (CDC) in Atlanta has adopted the 
recommendation of a two-step test protocol including 
an ELISA or an indirect immunofluorescent assay 
as screening test, followed by a confirmatory test 
(immunoblot). The value of immunoblots has been 
demonstrated by several European scientists [ 16-20]. 
The serologic response to a borrelia infection is 
complex, as the delay in the development of detectable 
antibodies may vary in different individuals. At the 
early stage of Lyme borreliosis, the immune response 
develops slowly and is not highly specific to the 
infecting Borrelia species. As the disease progresses 
towards advanced stages, the serologic pattern becomes 
more specific and, in such cases, it is advisable to use 
target antigens prepared with the suspected infecting 
strain. As described by Norman et a1 [21], European 
sera were generally more reactive to blots prepared 
with B. p r i n i i  or B. aJzelii antigens. However, cross- 
reactivity is usually observed between the three major 
Borrelia species encountered in Europe. 
O n  the basis of home-made immunoblots, we 
developed a new test which is easier to read and 
to interpret. In order to improve the stabdity of the 
components, we changed part of the immunoblot 
procedures, shortened the incubation time and intro- 
duced scores for interpretation to provide semiquan- 
titative results. 
MATERIALS AND METHODS 
Patients’ and controls‘ sera 
We evaluated 164 serum samples with IgG immunoblot 
and 116 with IgM immunoblot. All samples were 
collected from patients with a clinical diagnosis of 
Lyme disease (EM or other symptoms) and a positive 
screening test (VIDAS Lyme IgG + IgM, BioMkrieux, 
France). Erythema migrans: IgG, n=35; IgM, n=35; 
among these sera, five samples with a negative screening 
test were included, as they originated from patients 
known to have shown a seroconversion after a few 
weeks. Neuroborreliosis: IgG, n=61; IgM, n=50; all 
but two of these sera corresponded to patients with 
intrathecal antibody production. The two remaining 
samples were positive with serum and negative with the 
corresponding cerebrospinal fluid (CSF) for all anti- 
body tests, but CSF samples were positive by culture. 
The index of intrathecal antibody production was 
calculated as follows: IgG-specific CSF/serum divided 
by albumin CSF/serum (negative below 2.0). ACA: 
IgG, n=27; IgM, n= l l .  Lyme arthritis: IgG, n=41; 
IgM, n=20. 
All serum samples from patients with Lyme 
borreliosis and controls were selected by the follow- 
ing methods. Home-made IgG immunoblot [22]: 
Freka Borrelia-G ELISA (Fresenius, Bad Hormburg, 
Germany); Enzygnost Borreliosis IgG (Behringwerke, 
Marburg, Germany); B. bugdo$eri IgG EIA (Virion Int. 
Riischlikon, Switzerland). Home-made IgM immuno- 
blot [22]: Freka Borrelia-M ELISA (Fresenius, Bad 
Hormburg, Germany); Enzygnost Borreliosis IgM 
(Behringwerke, Marburg, Germany). Samples found 
positive in three out of the four IgG tests or two out of 
the three IgM tests were considered respectively as true 
IgG positives or IgM positives. To assess specificity of 
the immunoblot, control serum samples from syphilis 
patients (n =12), from patients with acute Epstein-Barr 
virus infection (EBV) (n=9)  or from patients with 
circulating autoimmune markers (rheumatoid factors 
(n=11), ANA (n=8),  anti-DNA antibodies (n=10)) 
were tested by immunoblot for Lyme IgG and IgM 
antibodies. 
Serum samples from blood donors were randomly 
selected in two transfusion centers in Switzerland, the 
first one in a low endemic region (Sion, n=80), and the 
other in a medium endemic region (Lausanne, n=100),  
and were tested for Lyme IgG and IgM antibodies. 
These samples were tested by immunoblot only. 
Methods 
Antigen preparation 
B. garinii (strain VS 102) was cultured in BSK I1 
medium. During the late-log-phase growth, the culture 
was centrifuged at 14 0002 for 15 f i n ,  washed twice 
in phosphate-buffered saline (PBS) pH 7.2 with addition 
of MgC12 (5 mM), and finally resuspended in distilled 
water a t  a protein concentration of 1 mg/mL Washed 
borreliae were stored a t  -80°C until use [4]. 
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SDS-PAGE and Western blotting 
SDS-PAGE and Western blot were performed as 
previously described [23]. Final protein concentrations 
were 0.25 mg/mL for IgG immunoblot and 0.08 
mg/mL for IgM immunoblot. Samples were heated for 
5 min at 95°C before undergoing electrophoresis on 
a polyacrylamide gel at 12.5% (constant voltage 170 V). 
The standard molecular weight of BioRad (low- 
range protein molecular weight standards) was used 
as reference for the calculation of relative molecular 
weights. After electrophoresis, proteins were transferred 
by Western blotting to polyvinylidene fluoride (PVDF) 
membranes. The blots were blocked with nonfat dry 
milk in PBS and cut into strips. 
lrnrnunoblots 
B. garinii antigen strips were incubated for 1 h with 
patient samples (diluted 1:100). After washing, rabbit 
(Flagellin] 
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41 kDa 
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Figure 1 Typical immunoblot profiles for the positive 
controls and for the sera of patients with specific symptoms 
of Lyme borreliosis: 1, positive control IgG; 2, positive 
control IgM; 3, patient with arthritis IgG; 4, patient with 
ACA IgG; 5, patient with neuroborreliosis IgG; 6, patient 
with neuroborreliosis Igh4; 7, patient with erythema 
migrans IgG; 8, patient with erythema migrans IgM. 
Protein bands with molecular masses of 93, 83, 75, 66, 60, 
55, 46, 41, 39, 37, 32.5, 30, 28, 22 and 18 kDa are 
regularly detected by the positive IgG control. Protein 
bands with molecular masses of 93, 60, 41, 37, 32.5 and 
22-23 kDa were regularly detected by the positive IgM 
control. 
antihuman IgG or IgM conjugated to horseradish 
peroxidase was added. At the end of a second 1 h 
incubation, unbound conjugate was removed by wash- 
ing. The bound conjugate was visualized by the 
addition of a chromogenic substrate (TMB). After 10 
min, washing with distilled water si:opped the reaction. 
The 3-h procedure was performed at room tempera- 
ture. Reactive bands observed on each strip were scored 
from 1 to 3 points according to the band intensity. 
Typical immunoblot profiles are presented in Figure 1. 
Criteria for irnmunoblot positivity 
The Lyme immunoblot assays utilize a template con- 
sisting of a developed antigen strip cut from the 
membrane used to prepare the antigen strips of the kit. 
This strip has been exposed to a pool of positive sera 
in order to exhibit bands representative of a Lyme 
infection. Protein bands are listed on the right side of 
the template. The control strip was used to identify 
and to score the protein bands ehbi ted  by the patients' 
sera. Although the protein bands with molecular masses 
of 93 (p100), 83, 75, 66, 60, 55, 46, 41 (flagellin), 39 
(p39), 37, 32.5 (OspA), 28, 22 (OspC), 18 and 12 kDa 
were regularly detected and scored i@om 1 point, faint 
band, to 3 points, dark band), only those with mole- 
cular masses of 93 (plOO), 41, 39 (p39), 32.5 (OspA) 
and 22kDa (OspC) were considered to establish the 
final positivity or negativity. All these proteins were first 
identified by monoclonal antibodies: 181.1 (p93), 
H9724 (flagellin), p39, H5332 (OspA), LA22 2B8 
(OspC) (kindly provided by A.G. Eiarbour, University 
of California, Irvine CA; WT. Golde, CDC, Fort 
Collins CO; T. Schwan, Rocky Mcuntain Laboratory, 
Hamilton MT, USA B. Wilske, MIX von Pettenkofer 
Institute, Munchen, Germany). 
The scores were summed up for each patient 
specimen and interpreted as shown in Table 1. 
RESULTS 
Sensitivity of the immunoblots 
IgG immunoblot detected 138 positive samples among 
the 164 patients with Lyme borreliosis, and 58 sera 
were positive among the 116 tested by IgM immuno- 
blot. The percentages of true positives observed with 
the different population groups are summarized in 
Table 2. For EM, the seropositivity rate was 66% for 
IgG tests and 49% for IgM tests. The five serum samples 
with a negative screening test were found to be negative 
in immunoblot. The sensitivity of the assay can be 
substantially increased with IgG and IgM simultaneous 
testing. The combined sensitivity reached 90%. The 
group of patients with neuroborreliosis included early 
infections (facial palsy) as well as late infections. The 
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was conunonly recognized by sera from patients with 
EM (100% for IgG and 89% for IgM), neuroborreliosis 
(100% and 90%), ACA (100% and 91%), arthritis (100% 
and loo%), syphilis (100% and 25%), EBV infections 
(100% and loo%), and autoimmune markers (93% and 
55%), and by sera from blood donors (84% and 60% in 
the low endemic region versus 98% and 76% in the 
medium endemic region). The 18-kDa and 39-kDa 
proteins were frequently observed in Lyme borreliosis 
cases, particularly in late infections. The 18-kDa 
patients was recognized by IgG in 89% and 88% of sera 
from patients with ACA and arthritis versus 26% for 
EM and 39% for neuroborreliosis. The 39-kDa protein 
was recognized by IgG in 74% of ACA and 90% of 
arthritis cases compared to 26% of EM and 51% of 
neuroborreliosis cases. The IgG response to the 93-kDa 
antigen usually appeared with a maximum intensity in 
the sera of patients with ACA (2.8) and arthritis (2.9). 
It should be noticed that sera with cross-reactivity 
recognized this band less frequently (25-41%), with 
moderate intensity (1.3-1.7). The OspC is a specific 
band, often recognized by IgG of sera from patients 
with Lyme borreliosis. Even if the intensity of the 
reaction to OspC with serum samples from patients 
with syphilis was high (3.0), this antigen was rarely 
recognized by these sera (8%). 
DISCUSSION 
We evaluated a total of 394 samples (164 sera from 
patients with clinical and laboratory findings consistent 
with Lyme borreliosis and 230 controls and blood 
donors). The overall sensitivities for the combined IgG 
and IgM were 91% and 98% for early versus late Lyme 
borreliosis. The overall specificities were 94% for IgC 
immunoblot and 97% for IgM immunoblot. Sero- 
prevalence in blood donors was tested in areas of low 
and moderate endemicity The percentages of sero- 
positivity found in these regions were in agreement 
with those found by Aeschhnann in 1986 [24] and 
by Satz in 1988 [25]. Positive results reflect a post- 
exposure to Borreliu that, in most cases, has not induced 
Lyme borreliosis. 
The CDC guidelines for the serodiagnosis of Lyme 
disease rely on a two-step approach. For the first test, 
the CDC recommends a sensitive EIA or immuno- 
fluorescence assay, and the second test should be 
performed on positive samples by immunoblotting. 
The assay method selected for the screening test should 
be sensitive but not over-sensitive in order to eliminate 
samples with very low levels of immunoreactivity 
towards borrelia antigens. Most screening tests currently 
available are based upon B. burgdovferi sensu stricto target 
antigens. As described by Hauser [17], European 
patients’ sera are more reactive in immunoblot with B. 
ufzelii and B. gurinii than with B. burgdofen sensu stricto. 
As the interpretation scheme recommended by 
Dressler et a1 [26] could not be applied to our 
immunoblots, because it would reduce the test sensi- 
tivity in early borreliosis, we developed immunoblots 
that are easier to read and to interpret, designing our 
own criteria. Scores were allocated to five specific 
bands according to the intensity of the reaction and s i x  
points divided between three of the five key bands are 
needed to report a positive IgG immunoblot. For the 
IgM immunoblot, four points, includmg a score for the 
OspC and the flagellin bands, are sufficient for a 
positive result. These simple guidelines are fairly simdar 
to those described by Engstrom et al [16]. Furthermore, 
as previously suggested by Norman et a1 [21], validation 
of immunoblot criteria should be done for each specific 
strain. 
EM is one of the most challenging situations for 
the serodiagnosis of Lyme borreliosis, as the immuno- 
logic reaction may be weak or delayed in some patients. 
Usually, paired sera are required for a precise diagnosis, 
but, when treated early, some patients will never 
seroconvert [27]. Parallel IgG and IgM immunoblotting 
sipficantly increases the sensitivity of the confirmatory 
test. In most cases, strong reactivities to flagehn and 
OspC were observed in early Lyme borreliosis, fol- 
lowed by a progressive increase of antibodies to other 
proteins. Nevertheless, the high sensitivity that we 
observed in our study is likely to result from a bias in 
the selection of cases. All the patients enrolled in this 
part of the study had not only a clinical diagnosis of 
EM, but also had a positive serology by a screening test 
confirmed by another immunoblot. This may also 
explain the relatively high frequency (43%) of IgG 
immunoreactivity against OspA, contrasting with known 
IgG immunoreactivity to this protein in early Lyme 
borreliosis [28]. If sera had been randomly selected 
from patients with EM only, the sensitivity of the 
immunoblot during the first stage would drastically 
decrease. 
Serologic findings from patients with neurobor- 
reliosis are difficult to interpret without a reasonable 
knowledge of the clinical background, as this group 
includes early stages (facial palsy) as well as late in- 
fections with intrathecal antibody production. The first 
stage of neuroborreliosis is characterized by a positive 
IgM response and negative or weak IgG response 
which will, in a second phase, increase progressively 
(Figure 1). However, some patients may have a negative 
serology (IgG and IgM) [9]. Apparent delays in sero- 
conversion may be caused by an immune response 
against specific antigens from one particular Borreliu 
isolate !9]. In most cases, these patients will develop 
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antibodies against antigens common to B. bugdorferi 
sensu lato at  a later stage, although reactivity against 
infecting Borreliu species will remain stronger. In 
Switzerland, about two-thirds of neuroborreliosis 
patients exhibited a preferential reactivity to B. garinii 
isolates [9]. 
IgM seroreactivity is usually absent in advanced 
stages, and IgM immunoblotting does not improve the 
sensitivity of the confirmatory test for ACA. The only 
false-negative IgG result that we observed was due to 
an infection by B. afielii.  This finding is uncommon, 
as, in advanced cases like arthritis, ACA and chronic 
neuroborreliosis, the immunoreactivity is intense, 
with strong cross-reactions for all B. burgdovferi species 
(Figure 1 ) .  Nevertheless, some patients develop anti- 
body patterns extremely specific for the infecting strain, 
and their sera may not react in serologic tests using 
antigens from another Borreliu species. 
Among all the bands that we could detect, the 
flagehn was the most frequent. Antibodies against 
flagehn were present not only in all stages of Lyme 
disease but also in the sera of blood donors, and of 
patients with syphlis, EBV or autoimmune disease. 
These cross-reactions are known to be caused by other 
bacterial infections. Nevertheless, immunoreactivity to 
the flagellin band has to remain an important element 
of a positive blot for Lyme disease. In our study, the 
most significant and specific markers for late borreliosis 
were the 18- and 39-kDa bands. Although these two 
bands appear with high intensity, no cross-reaction was 
found for these proteins in sypllis patients, in 
agreement with the study of Simpson et al [29]. Their 
detection rate was also negligible among blood donors, 
but their frequencies were 89% for ACA and 88% for 
arthritis. More work would be needed to re-evaluate 
our interpretation criteria with the inclusion of the 18- 
kDa band, at least in defined clinical settings. The 93- 
k D a  protein was found to be a good marker for late- 
stage Lyme borreliosis, as described by Zoller et al [ZO]. 
IgG and IgM immune responses to the OspC 
protein were found in the earlier stages of infections, 
with low cross-reactivity in controls [30]. In our study, 
IgG and IgM antibody reactivity to OspC appeared as 
immunodominant bands in the serum samples from 
patients with Lyme borreliosis, with good specificity. 
However, curiously, the OspC appears faintly in ACA. 
Nevertheless, it might be used as a significant marker 
for Lyme borreliosis, particularly in the early stage of 
the disease. 
Immunoblot assays based upon hfferent Borreliu 
strains may prove particularly useful in western, central 
and eastern Europe and in Asia to confirm human 
Lyme borreliosis [17]. The kits that we have developed 
and evaluated are both sensitive and specific for 
detecting borrelia antibodies. Using the kit template, 
the position and the intensity of \:he stained bands can 
be easily correlated with well-defined borrelia antigens. 
The total score makes easier a final decision on inter- 
pretation of the immunoblots. 
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